What are Pacira BioSciences, Inc.'s total assets?

Pacira BioSciences, Inc. (PCRX) holds $1.2B in total assets, down 23.8% year over year.

How much debt does Pacira BioSciences, Inc. have?

Pacira BioSciences, Inc. carries $411.2M in total debt against $653.9M of shareholders' equity, a debt-to-equity ratio of 0.63.

How much cash does Pacira BioSciences, Inc. have?

Pacira BioSciences, Inc. holds $144.3M in cash and equivalents.

Can Pacira BioSciences, Inc. cover its short-term obligations?

Its current ratio is 4.73 — current assets exceed current liabilities.

Where does Pacira BioSciences, Inc.'s balance sheet data come from?

Every line is extracted from Pacira BioSciences, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.

Pacira BioSciences, Inc. PCRX Balance Sheet Statement

Income Statement Balance Sheet Cash Flow Ratios Segments

Quarterly Annual TTM

YoY

Simplified Detailed

	FY'25	FY'24	FY'23	FY'22
Cash and cash equivalents	$158.55M-42.7%	$276.77M+80.5%	$153.3M+47.2%	$104.14M-82.2%
Short-term investments	$79.88M-61.6%	$207.84M+65.9%	$125.28M-32.1%	$184.51M+160%
Accounts receivable, net	$124.07M+9.5%	$113.3M+7.3%	$105.56M+7.3%	$98.4M+2.2%
Inventories	$152.86M+22.0%	$125.28M+20.1%	$104.35M+8.6%	$96.06M-2.5%
Raw materials	$43.34M-14.7%	$50.8M-6.1%	$54.1M+35.9%	$39.81M+9.6%
Work in process	$28.2M+3.0%	$27.38M-12.3%	$31.22M+8.2%	$28.85M-18.0%
Finished goods	$81.33M+72.7%	$47.1M+147%	$19.04M-30.5%	$27.4M+1.4%
Prepaid expenses and other current assets	$32.62M+48.7%	$21.93M+2.0%	$21.5M+41.3%	$15.22M+3.1%
Income taxes receivable	$8.2M—	——	——	——
Total current assets	$547.97M-26.5%	$745.13M+46.1%	$509.99M+2.3%	$498.33M-42.5%
Property and equipment, net	$140.69M-15.8%	$167.17M-3.9%	$173.93M-5.2%	$183.51M-2.6%
Accumulated depreciation	$137.7M+3.6%	$132.93M-1.8%	$135.31M+15.2%	$117.48M+37.8%
Operating lease right-of-use assets	4,177,700,000%-744,500,000%	4,922,200,000%-1,179,800,000%	6,102,000,000%-985,700,000%	7,087,700,000%-553,300,000%
Goodwill	$20.21M—	$0-100%	$163.24M0.0%	$163.24M+12.4%
Intangible assets, net	$333.82M-21.6%	$425.97M-11.9%	$483.26M-10.6%	$540.55M-13.4%
Total assets	$1.26B-18.6%	$1.55B-1.3%	$1.57B-6.4%	$1.68B-19.0%
Accounts payable	$15.15M-20.8%	$19.13M+21.9%	$15.7M+3.1%	$15.22M+44.4%
Accrued expenses	$37.84M-52.8%	$80.12M+24.7%	$64.24M-28.4%	$89.79M-29.6%
Operating lease liabilities, current	$9.84M+10.7%	$8.89M+1.0%	$8.8M-3.5%	$9.12M+15.6%
Income taxes payable	$6.1M+19.6%	$5.1M+410%	$1M—	$0-100%
Accrued interest	$782K+56.4%	$500K+25.0%	$400K-50.0%	$800K+700%
Total current liabilities	$120.59M-61.1%	$309.92M+218%	$97.38M-34.1%	$147.77M-71.6%
Long-term debt	$372.19M+257%	$104.21M-9.5%	$115.2M-54.1%	$251.06M-25.1%
Operating lease liabilities, non-current	$36.18M-19.0%	$44.65M-18.5%	$54.81M-15.4%	$64.8M-9.7%
Operating Lease Liabilities (Total)	$46.02M-14.0%	$53.53M-15.8%	$63.61M-14.0%	$73.92M-7.2%
Asset retirement obligations	$3.9M-7.1%	$4.2M-2.3%	$4.3M+30.3%	$3.3M+37.5%
Other non-current liabilities	$20.57M+22.3%	$16.82M+23.9%	$13.57M+40.4%	$9.67M-51.6%
Total liabilities	$571.81M-26.2%	$775.17M+10.1%	$704.26M-22.3%	$906.19M-32.6%
Preferred stock	$0—	$0—	$0—	$0—
Common stock	250M+531,815%	47K+2.2%	46K0.0%	46K+2.2%
Additional paid-in capital	$1.06B+5.5%	$1.01B+3.4%	$976.63M+5.7%	$924.1M-1.9%
Retained earnings	-$199.32M+3.4%	-$206.36M-93.2%	-$106.8M+28.2%	-$148.75M+29.8%
Accumulated other comprehensive income (loss)	$4.33M+1,162%	$343K+38.9%	$247K+165%	-$380K-328%
Treasury stock	$176.57M+603%	$25.12M—	$0—	——
Total stockholders' equity	$693.11M-11.0%	$778.35M-10.5%	$870.13M+12.3%	$775.01M+6.1%
Total liabilities and stockholders' equity	$1.26B-18.6%	$1.55B-1.3%	$1.57B-6.4%	$1.68B-19.0%
Available-for-Sale Debt Securities - Amortized Cost	$79.85M-61.6%	$207.69M+62.7%	$127.63M-42.6%	$222.52M+215%
Finished goods	$81.33M+72.7%	$47.1M+147%	$19.04M-30.5%	$27.4M+1.4%
Finite-Lived Intangible Assets - Expected Amortization Expense (Year One)	——	——	——	——
Finite Lived Intangible Assets - Gross	$590.09M0.0%	$590.09M0.0%	$590.09M0.0%	$590.09M0.0%
Intangible Assets Gross (Excluding Goodwill)	$624.37M-0.1%	$624.96M0.0%	$624.96M0.0%	$624.96M-4.0%
Investments - Amortized Cost Basis	$79.85M-61.6%	$207.69M+62.7%	$127.63M-42.6%	$222.52M+215%
Net Investment in Lease	$41.78M-15.1%	$49.22M-19.3%	$61.02M-13.9%	$70.88M-7.2%
Deferred tax assets	$123.85M-5.0%	$130.38M-9.8%	$144.49M-9.9%	$160.31M+4.5%
Investments and other assets	$22.31M-37.4%	$35.65M-1.1%	$36.05M+32.7%	$27.17M+23.6%
Intangible assets — net	$333.82M-14.6%	$391.1M-12.8%	$448.39M-11.3%	$505.68M-10.2%
Other intangible assets—net	$368.1M-13.6%	$425.97M-11.9%	$483.26M-10.6%	$540.55M-13.4%
Operating lease right-of-use assets	$41.78M-15.1%	$49.22M-19.3%	$61.02M-13.9%	$70.88M-7.2%
Property, plant and equipment at cost	$278.39M-7.2%	$300.1M-3.0%	$309.23M+2.7%	$300.99M+10.0%
Short-term investment securities (includes restricted investments of consolidated variable interest entities: 2026, $85; 2025, $84)	$79.88M-61.6%	$207.84M+65.9%	$125.28M-32.1%	$184.51M+160%
Operating Lease Right-of-Use Assets in Other Assets	$41.78M-15.1%	$49.22M-19.3%	$61.02M-13.9%	$70.88M-7.2%
Accrued Manufacturing Costs	$37.84M—	——	——	——
Other Commercial Liabilities	$95.6M+19.3%	$80.12M+24.7%	$64.24M-28.4%	$89.79M-29.6%
Accrued Income Taxes, Current	$100K-85.7%	$700K—	——	——
Accrued Liabilities, Current	$95.6M+19.3%	$80.12M+24.7%	$64.24M-28.4%	$89.79M-29.6%
Compensation and benefits	$37.84M—	——	——	——
Current portion of accrued product warranty	$11.55M—	——	——	——
Lease Liability Payments - 2020 (Remaining Three Months)	——	——	——	——
Operating Lease Liability Payments - 2024 (Lessee)	——	——	——	——
Operating Lease Liability Payments - 2025 (Lessee)	——	——	——	——
Lease Liability Payments - Due Year Two	——	——	——	——
Lease Liability Payments - Due Year Three	——	——	——	——
Lease Liability Payments - Due Year Four	——	——	——	——
Lease Liability Payments - Remainder of Fiscal Year	——	——	——	——
Operating Lease Liability Payments Due	——	——	——	——
Operating Lease Liability - Undiscounted Excess Amount	——	——	——	——
Standard Product Warranty Accrual	$11.55M—	——	——	——
Operating Lease Liability Payments - 2026 (Lessee)	——	——	——	——
Operating Lease Liability Payments - 2027 (Lessee)	——	——	——	——
Operating Lease Liability Payments - 2028 (Lessee)	——	——	——	——
Total debt	$418.2M-25.5%	$561.3M+199%	$187.45M-42.3%	$324.98M-57.5%
Common Stock Par Value Per Share	$0.000.0%	$0.000.0%	$0.000.0%	$0.000.0%
Common Stock Shares Issued	47.9M+1.7%	47.1M+1.3%	46.5M+1.2%	45.9M+2.7%
Convertible Preferred Stock Authorized Shares	5M0.0%	5M0.0%	5M0.0%	5M0.0%
Convertible Preferred Stock Issued Shares	0—	0—	0—	0—
Convertible Preferred Stock Outstanding Shares	0—	0—	0—	0—
Common stock; $0.001 par value; 6,000 shares authorized; 3,755 and 3,751 shares issued and outstanding as of March 31, 2026 and December 31, 2025, respectively	$48K+2.1%	$47K+2.2%	$46K0.0%	$46K+2.2%
Preferred stock; $0.001 par value; 100 shares authorized; no shares issued and outstanding	$0—	$0—	$0—	$0—
Preferred Stock Par Value Per Share	$0.000.0%	$0.000.0%	$0.000.0%	$0.000.0%
Share-Based Payment Award Options Outstanding - Number	6.4M-6.9%	6.8M-3.3%	7.1M+12.9%	6.3M+3.7%
Share Price	——	——	——	——
Share Repurchase Authorization Limit	——	——	——	——
Share Repurchase Program - Amount Remaining	——	——	——	——
Unrealized Gains on Investments	$40K-80.9%	$209K+88.3%	$111K+344%	$25K-86.3%
Unrealized Losses on Investments (Before Tax)	$13K-78.3%	$60K+22.4%	$49K-94.0%	$819K+40,850%
Weighted Average Exercise Price of Outstanding Options	$40.65-5.4%	$42.95-13.1%	$49.40-5.7%	$52.38+6.2%
Cumulative Cost Basis	$79.85M-61.6%	$207.69M+62.7%	$127.63M-42.6%	$222.52M+215%
Fair Value Measurement Disclosure	$10.25M-63.1%	$27.78M-0.8%	$28.01M+32.2%	$21.19M+16.1%
Accrued production costs	$9M—	——	——	——
Accrued research and development expenses	$6.13M—	——	——	——
Accrued selling, general and administrative expenses	$17.43M—	——	——	——
Asset Retirement Obligation	$3.9M-7.1%	$4.2M-2.3%	$4.3M+30.3%	$3.3M+37.5%
Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax	$13K-78.3%	$60K+22.4%	$49K-94.0%	$819K+40,850%
Gross Unrealized Gains	$40K-80.9%	$209K+88.3%	$111K+344%	$25K-86.3%
Total	$79.85M-61.6%	$207.69M+62.7%	$127.63M-42.6%	$222.52M+215%
Common stock, par value (in dollars per share)	$00.0%	$00.0%	$00.0%	$00.0%
Common stock, shares authorized (in shares)	$250M0.0%	$250M0.0%	$250M0.0%	$250M0.0%
Common stock, shares issued (in shares)	$47.89M+1.7%	$47.08M+1.3%	$46.48M+1.2%	$45.93M+2.7%
Common Stock, Shares, Outstanding	$41.12M-11.1%	$46.24M-0.5%	$46.48M+1.2%	$45.93M+2.7%
Contingent consideration	$18.07M-10.7%	$20.24M-18.0%	$24.7M-12.2%	$28.12M-51.2%
Deferred income taxes	$4.21M—	$0—	——	——
Gross deferred tax assets, deduction year two	——	$62.3M—	——	——
Gross deferred tax assets, deduction year one	——	$62.3M—	——	——
R&D credit carryforward	——	$124.6M—	——	——
Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Value	$10.25M-63.1%	$27.78M-0.8%	$28.01M+32.2%	$21.19M+16.1%
Amortization expense, seventh period	——	——	——	——
Amortization expense, sixth period	——	——	——	——
Finite-Lived Intangible Assets, Accumulated Amortization	$256.27M+28.8%	$198.99M+40.4%	$141.7M+67.9%	$84.41M+211%
2028	——	——	——	——
2030	——	——	——	——
2031	——	——	——	——
Remainder of 2026	——	——	——	——
2027	——	——	——	——
2029	——	——	——	——
Gross Carrying Amount	$590.09M0.0%	$590.09M0.0%	$590.09M0.0%	$590.09M0.0%
Tax receivable within other current assets	$8.2M—	——	——	——
Indefinite- lived intangible impairment	$624.37M-0.1%	$624.96M0.0%	$624.96M0.0%	$624.96M-4.0%
Lessee Operating Lease Liability Payments Due	——	——	——	——
Thereafter	——	——	——	——
Lessee Operating Lease Liability Undiscounted Excess Amount	——	——	——	——
Increasing modestly period	——	——	——	——
Number of embedded leases	——	——	——	——
Operating Lease Weighted Average Discount Rate Percent	——	——	——	——
Other accrued liabilities	$12.86M—	——	——	——
Preferred Stock, Par or Stated Value Per Share	$00.0%	$00.0%	$00.0%	$00.0%
Preferred Stock, Shares Authorized	$5M0.0%	$5M0.0%	$5M0.0%	$5M0.0%
Preferred Stock, Shares Issued	$0—	$0—	$0—	$0—
Preferred Stock, Shares Outstanding	$0—	$0—	$0—	$0—
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number	$6.37M-6.9%	$6.85M-3.3%	$7.08M+12.9%	$6.27M+3.7%
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price	$40.65-5.4%	$42.95-13.1%	$49.4-5.7%	$52.38+6.2%
Share price (in dollars per share)	——	——	——	——
Accrued excise taxes	——	——	——	——
Share Repurchase Program, Authorized, Amount	——	——	——	——
Share Repurchase Program, Remaining Authorized, Amount	——	——	——	——
Treasury stock, shares (in shares)	$6.77M+709%	$837.24K—	$0—	——
Remainder of Fiscal Year 2024	——	——	——	——
Remainder of Fiscal Year 2025	——	——	——	——

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Ask your AI about Pacira BioSciences, Inc..

Connect your AI assistant and get a quick read on the numbers, right in your chat.

Connect your AI

Claude

Questions, answered.

What are Pacira BioSciences, Inc.'s total assets?: Pacira BioSciences, Inc. (PCRX) holds $1.2B in total assets, down 23.8% year over year.
How much debt does Pacira BioSciences, Inc. have?: Pacira BioSciences, Inc. carries $411.2M in total debt against $653.9M of shareholders' equity, a debt-to-equity ratio of 0.63.
How much cash does Pacira BioSciences, Inc. have?: Pacira BioSciences, Inc. holds $144.3M in cash and equivalents.
Can Pacira BioSciences, Inc. cover its short-term obligations?: Its current ratio is 4.73 — current assets exceed current liabilities.
Where does Pacira BioSciences, Inc.'s balance sheet data come from?: Every line is extracted from Pacira BioSciences, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.